Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Edith Perez on T-DM1 and the MARIANNE Trial

December 13th 2013

Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 as a treatment for patients with breast cancer.

No Survival Benefit Found in LRT for Women Presenting With Metastatic Breast Cancer

December 13th 2013

In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),

PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer

December 13th 2013

PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.

Dr. Brufsky Discusses the tnAcity Trial in TNBC

December 13th 2013

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

Exercise Reduces Joint Pain in Breast Cancer Patients Treated With Aromatase Inhibitors

December 13th 2013

A prescribed exercise program reduces joint pain in breast cancer survivors taking AIs, with pain reductions observed at all levels of exercise.

Anastrozole Cuts Breast Cancer Incidence in Half for Women at High Risk

December 13th 2013

Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.

NeoALTTO Analysis Finds Significant Link Between pCR and Survival

December 12th 2013

Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer

December 12th 2013

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC

December 12th 2013

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.

Dr. Arteaga Discusses the CALGB 40603 Trial

December 12th 2013

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery

December 12th 2013

Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.

Dr. Kent Osborne Discusses the PRIME 2 Trial

December 12th 2013

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

Benefits of Screening Mammography Not So Inconsistent, After All

December 12th 2013

The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.

High Levels of Infiltrating Lymphocytes May Identify Better Response to Trastuzumab

December 12th 2013

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

Dr. Jennifer Litton on the Phase III BETH Trial

December 11th 2013

Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial.

Dr. Loi on the Association Between TILs and Trastuzumab

December 11th 2013

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

Mammogram Study Provides Rationale for Expanding Screening Programs

December 5th 2013

Most deaths from breast cancer occur in women who have not been regularly screened and whose tumors are diagnosed at a median age 49 years, confirming the need for the greater use of annual mammography in younger women, according to a recent study that marks the latest episode in the debate over screening guidelines.

Dr. McTiernan on Biomarkers in Breast Cancer

December 4th 2013

Anne McTiernan, MD, PhD, research professor of epidemiology, University of Washington, member, Fred Hutchinson Cancer Research Center, discusses the biomarkers that are associated with poor prognosis in patients with breast cancer.

Dr. Finn on AMG900 in Breast Cancer

December 2nd 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

Quest Diagnostics Launches New BRCA 1/2 Test

December 2nd 2013

Quest Diagnostics, a business founded 46 years ago in a medical resident's two-room apartment, has parlayed the exponential subsequent growth in medical testing into an operation worth $8.5 billion.